RE: Tensred30 Jan 2022 18:07
Got it now
Our rns of May 2019
https://www.optibiotix-ir.com/content/news/archive/2019/20-05-19
Nutrilinea, based near Milan in northern Italy, is a manufacturer of food supplement formulations containing probiotics, with over 15 years' experience in the development of products for the food and pharmaceutical industries in Europe and the United States. It is one of OptiBiotix's preferred manufacturers, and currently produces the Company's CholBiome®, CholBiome®x3 and SlimBiome® Medical products. Nutrilinea has technology that enables the production of multilayer tablets used in CholBiome®x3 which will also be used for this new product.
Goetz partners note (on page 26) provided this
May-19 LPLDL Nutrilinea Srl. (Europe ex-UK) License agreement for use of LPLDL in a food supplement (TensRed) for reduction of high blood pressure. Nutrilinea covers cost of product development, manufacturing & human studies, has 12 mos exclusivity in Europe. ProBiotix has exclusivity for UK & all other markets ex-Europe.
Nutrilinea merged with biopharma in late 2019
and now apparently group sold
MILAN, Jan 17 2022 (Reuters) - European private equity firm Ardian struck a deal to buy the majority of Italy's Biofarma Group from White Bridge Investments in order to boost further the international growth of the drug company, a statement said on Monday.
The Scarpa family, which founded the group, will keep a 30% stake in the drug firm and Maurizio Castorina will continue to lead Biofarma as chief executive, it added without providing financial details of the deal.
On Sunday two sources with knowledge of the matter told Reuters Ardian had signed the takeover agreement for about 1.1 billion euros ($1.26 billion).
White Bridge, led by former BC Partners investor Marco Pinciroli, took control of Biofarma in 2019 by merging it with its portfolio company Nutrilinea. Ardian entered exclusive talks to buy Biofarma from owner White Bridge Investments earlier this year, after trumping a rival offer from buyout fund BC Partners, one of the sources said on Sunday.
Biofarma, specialised in food supplements, probiotic-based drugs and cosmetics, reported revenue of 230 million euros in 2021, of which around 50% from sales abroad.
still available on alibaba btw
mol